The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
- PDF / 399,108 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 26 Downloads / 163 Views
REVIEW
The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy Miao Yu
Received: January 29, 2020 Ó The Author(s) 2020
ABSTRACT This article summarizes a presentation from a recent symposium entitled ‘‘SUs in the treatment of T2DM: a fresh look and new insights’’ held on 18 September 2019 during the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, and discusses whether sulfonylureas (SUs) are a good ‘team player.’ It examines the likely impact of using SUs early in the course of type 2 diabetes mellitus (T2DM), either alone or in combination with other agents, on glycemic outcomes and net side effects. The management of patients with T2DM and cardiovascular disease or chronic kidney disease is discussed, highlighting how glycemic control and cardiorenal effects are equally important in these patients and chronic exposure to hyperglycemia should be minimized. The role of SU-based combination therapy in this patient group is explored, demonstrating how later-generation SUs, either as monotherapy or combined with Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12030369. M. Yu (&) Key Laboratory of Endocrinology, Department of Endocrinology, National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China e-mail: [email protected]
other antidiabetic drugs, help to ensure maximum benefits with minimal side effects. Evidence regarding the combination of SUs with a sodium-glucose transport protein 2 inhibitor shows that this might prove to be a good clinical option, especially in patients with renal impairment.
Keywords: Cardiovascular disease; Chronic kidney disease; Hyperglycemia; Sulfonylureas; Type 2 diabetes mellitus Key Summary Points Early glycemic control can help minimize the risk of chronic exposure to hyperglycemia and thus the cardio-renal effects of type 2 diabetes mellitus (T2DM) Evidence suggests that monotherapy or combination therapy with sulfonylureas (SUs) is an option for T2DM patients with cardiovascular disease or chronic kidney disease and in some countries (e.g., China) is the backbone of T2DM treatment in clinical practice Combining a later-generation SU with a sodium-glucose transport protein 2 inhibitor may ultimately prove to be a good clinical option, especially in those with renal impairment
Diabetes Ther
THE WORLDWIDE CHALLENGE OF GLYCEMIC CONTROL Average glycated hemoglobin (HbA1c) levels among patients with type 2 diabetes mellitus (T2DM) vary geographically worldwide between 7.5% in Germany and 8.6% in Mexico, Norway and India [1–3]. The National Health and Nutrition Examination Survey (NHANES) study in 1326 US adults with diabetes has demonstrated that the proportion of patients achieving glycemic targets has not improved over the last 20 years, despite the introduction of newer agents [4]. In 1999–2002, 44% and 59% of patients achieved individualized HbA1c t
Data Loading...
